At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 98 enrolled / 98 target
Drug / intervention
tisagenlecleucelbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II, Single Arm, Multicenter Open Label Trial to Determine the Efficacy and Safety of Tisagenlecleucel (CTL019) in Adult Patients With Refractory or Relapsed Follicular Lymphoma
In Brief
A Phase 2 clinical trial evaluating tisagenlecleucel for Follicular Lymphoma. Completed, enrolled 98 participants across 30 sites in 12 countries.
Signals
Enrolling slower than its timeline implies
Detailed Summary
This is a multi-center, phase II study to determine the efficacy and safety of tisagenlecleucel in adult patients with relapsed or refractory FL.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsFollicular Lymphoma
CountriesAustralia, Austria, Belgium, France, Germany, Italy, Japan, Netherlands, Norway, Spain, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
First PostedJun 2018
Enrollment StartNov 2018
Primary CompletionNov 2020
Study CompletionMay 2025
TodayJul 2026
First PostedJun 26, 2018
Enrollment StartNov 12, 2018
Primary CompletionNov 24, 2020
Study CompletionMay 28, 2025
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 8.0 years ago
Arms & Interventions
CTL019experimental
All patients who received tisagenlecleucel infusion.
Biological: tisagenlecleucel
Interventions
tisagenlecleucelbiological
Tisagenlecleucel is single infusion.